Are you at risk for colorectal cancer? Answer these 13 questions in less than 1 minute to find out.
Our Clinical Trial Finder is a one-stop place to find and learn more about high-impact research studies for patients with advanced CRC. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status.
Our Path to a Cure report is our plan for the future. This plan is not just for Fight CRC, but for everyone who is willing to champion this cause.
Shop our online store to raise awareness everywhere you go! From t-shirts and fanny packs to patient education resources, we have a little bit of everything.
Raise Awareness. Be an Advocate. Host an Event.
Program Status Clinical trial’s patient recruitment status
Phase Phase of the clinical trial that is recruiting (I, II, or III)
Immunotherapy-centered Trial A flag to indicate whether the trial is an immunotherapy trial
Prior Immunotherapy Allowed Whether the clinical trial is open to patients who have received prior immunotherapy
CRC-directed Trial A flag to indicate whether the trial is specifically targeting colon cancer, rectal cancer, or colorectal cancer patients
Drugs Therapeutics used in the clinical trial
Tags
Comments
Phase III trial (STELLAR-003), only for MSS CRC patients. Immunotherapy combination vs standard of care (SOC). Immunotherapy arm: XL092 (tyrosine kinase inhibitor (TKI)) in combination with atezolizumab (anti PD-L1, checkpoint inhibitor, immunotherapy) Standard of care arm: regorafenib (Stivarga) Key inclusion criteria: no prior Stivarga, Lonsurf, or anti PD-L1/PD-1 immunotherapies. Measurable disease. Prior trials of the TKI XL092 (alone or in combinations) (STELLAR-001, STELLAR-002) show that is active and safe. Prior trials of other TKI (cabozantinib) plus immunotherapies (COSMIC-021, CAMILLA) showed meaningful activity in mCRC. See Helpful Links
Helpful Links
Contacts
Inclusion Criteria
Inclusion Criteria:
Subjects with histologically or cytologically confirmed adenocarcinoma of the colon or rectum.
Documented RAS status (mutant or wild-type [WT]), by tissue-based analysis. Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.
Has received standard-of-care (SOC) anticancer therapies as prior therapy for metastatic CRC and has radiographically progressed, is refractory or intolerant to these therapies.
Systemic SOC anticancer therapy if approved and available in the country where the subject is randomized. Radiographic progression during treatment with or within 4 months following the last dose of the most recent approved SOC chemotherapy regimen. Measurable disease according to RECIST v1.1 as determined by the Investigator. Available archival tumor biopsy material. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization. Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy. Age 18 years or older on the day of consent. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Adequate organ and marrow function. Fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and after the last dose of treatment. Female subjects of childbearing potential must not be pregnant at screening.
Exclusion Criteria
Exclusion Criteria:
Prior treatment with XL092, regorafenib, trifluridine/tipiracil, or PD-L1/PD-1 targeting immune checkpoint inhibitors (ICIs). Receipt of a small molecule kinase inhibitor (including investigational agents) within 2 weeks before randomization. Receipt of any type of anticancer antibody therapy, systemic chemotherapy, or hormonal anti-cancer therapy within 3 weeks (or bevacizumab within 4 weeks) before randomization. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before randomization. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before randomization. Subject has uncontrolled, significant intercurrent or recent illness. Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 4 weeks prior to randomization. Systemic treatment with, or any condition requiring, either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to randomization. Corrected QT interval calculated by the Fridericia formula (QTcF) > 460 ms within 10 days before randomization. History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent. Pregnant or lactating females. Inability to swallow study treatment formulation, inability to receive IV administration, or presence of GI condition that might affect the absorption of study drug. Previously identified allergy or hypersensitivity to components of the study treatment formulations. Any other active malignancy or diagnosis of another malignancy within 2 years before randomization. Exceptions are noted in the protocol. Administration of a live, attenuated vaccine within 30 days before randomization.
NCT ID Trial ID number from clinicaltrials.gov or other database
Date Trial Added Date on which the clinical trial was added to the clinicaltrials.gov website
Updated Date Date on which the clinical trial was updated on the clinicaltrials.gov website